In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Inverness Medical Innovations nets $261.3mm with FOPO

Executive Summary

Inverness Medical Innovations (diagnostics and therapeutics for women's health, cardiovascular conditions, and infectious diseases) has netted $261.3mm through the follow-on public offering of 6.9mm common shares at $39.65 apiece. The company, which had initially planned to sell 5mm shares, intends to use a portion of the proceeds to repay debt.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • OTC, Consumer
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies